Abstract: The key words “chronic hepatitis B” and “guideline” were used to retrieve the PubMed database to
collect the domestic and international literature on the prevention and treatment of chronic hepatitis B guidelines,
the diagnostic criteria and treatment options of antiviral treatment were compared. We found that the diagnostic
criteria of antiviral therapy for chronic hepatitis B recommended by various guidelines were different. Chinese,
Asia Pacific, South Korea, Japan and the United States suggest that for HBeAg positive patients, HBV DNA ≥
(or ＞) 20000 IU/ml, for HBeAg negative patients, HBV DNA ≥ (or ＞) 2000 IU/ ml. Chinese, Asia Pacific,
South Korea and the United States propose ALT ≥ (or ＞) 2 × ULN; Europe, UK, WHO and Japan suggest
ALT to abnormal levels. The guidelines for the treatment plan of chronic hepatitis B antiviral treatment also
exists varying degrees of difference in five aspects, the type of drugs, whether to divide the first-line, second-
line and third-line drugs, treatment course, monitoring indicators and evaluation endpoints. Entecavir and
tenofovir disoproxil fumarate are common drugs almost recommended by all guidelines. We concluded that the
HBV DNA value of European, UK and WHO are simpler and more convenient for clinicians to operate in the
diagnosis of chronic hepatitis B antiviral therapy, and the recommendations of China, Asia Pacific, South Korea,
Japan and the United States are more rigorous. In terms of antiviral therapy for chronic hepatitis B, the advice of
WHO is the most simple, which only recommend entecavir and tenofovir disoproxil fumarate.